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constitutive ones include more precise control of expression and 
potential assessment of reversibility of expression. Targeted inacti-
vation and activation of neurotransmitter related genes, as well as 
those for other neuronally expressed genes, has allowed for more 
precise elucidation of the function of neurotransmitters and cir-
cuits within the CNS of the intact organism. Other approaches that 
involve selective expression of toxins within defined neural circuits 
have also been informative (Drago et al., 1998; Martin et al., 2002; 
Yu et al., 2004; Nakashiba et al., 2008). These methods, however, 
are not without their limitations. Non-inducible systems are often 
associated with confounding developmental issues, inducible sys-
tems are slow to turn on and off, eliminating expression of an 
endogenous gene or introduction of a constitutively active isoform 
can have confounding effects on a particular cell’s physiology with 
respect to its role in neuronal function, and toxins can damage or 
kill the neurons they are expressed in.
Recently,  transgenic  technologies  have  been  used  to  create 
novel systems able to primarily influence neuronal activity states. 
These systems rely upon targeted expression of particular recep-
tor proteins that, when activated, can inhibit or enhance neuronal 
activity. These approaches are more systems-based, allowing for 
functional analysis of distinct neuronal circuits as a whole, rather 
than examination of the role of a particular gene/protein within 
a neuron. One strategy has been to use potassium channels to 
inhibit neuronal activity. Both targeted expression of modified 
constitutively open potassium channels in Drosophila (Nitabach 
et al., 2002), and targeted expression of the inward rectifying Kir2.1 
IntroductIon
The perturbation of normal biological processes has been one of 
the primary strategies employed to investigate the role of specific 
genes, proteins, tissues, and neural circuits in the intact organism 
or system. A primary methodology long used to modify neuronal 
activity and function has been with pharmacological tools. The dis-
covery and utilization of agonist and antagonist ligands selective for 
specific neurotransmitter receptors and related signaling pathways 
and processes has allowed researchers to probe the role of select 
neuronal circuits in CNS function with tremendous power. Even 
so, there are certain limitations associated with pharmacological 
treatments, especially in vivo, that include off target affinities and 
undesired side-effects effects of drugs, and inability to effectively 
target a drug to act only in a restricted subset of tissues or neuro-
nal circuits normally expressing the target. A more recent method 
to study neuronal function has involved the creation and use of 
transgenic animals. Initially it was possible to only knock-out a 
gene or knock-in a modified gene systemically. Modified genes 
usually represented hypo- or hyperactive versions, or particular 
splice  isoforms.  Subsequent  developments  both  in  insect  and 
mammalian models allowed for the creation of expression systems 
where, through the use of a bipartite genetic system, transgene 
expression can be induced in defined tissues, and conditionally at 
defined time points by the administration of a drug, hormone, or 
temperature shift (Brand and Perrimon, 1993; Wells and Carter, 
2001; McGuire et al., 2004; Aiba and Nakao, 2007; Gaveriaux-Ruff 
and Kieffer, 2007). Advantages of inducible genetic systems over 
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potassium channel (Yu et al., 2004) in mice, have been found to be 
effective in silencing neuronal activity. To modulate neuronal activ-
ity, a system has been developed to target expression of GABAA chlo-
ride channels that respond to the allosteric modulator zolpidem 
within a transgenic mouse model insensitive to zolpidem (Wulff 
et al., 2007). Difficulties with these approaches include potential 
developmental effects of constitutively expressed channels, and 
temporal induction methods of expression can take days or weeks 
to become effective.
A very interesting approach to perform targeted modification 
of neuronal activity has involved the use of light to activate ion 
channels and proteins. One method utilizes targeted expression 
of a light-activated non-selective cationic channel protein iso-
lated from unicellular green algae, channelrhodopsin, to excite 
neuronal activity. (Nagel et al., 2003, 2005; Schroll et al., 2006; 
Lin et al., 2009). Whereas this is a very powerful method for rap-
idly activating neurons, channelrhodopsins are useful only for 
short-term neuronal modulation because they are hindered by 
rapid desensitization. Another light-based method that is used 
to promote neuronal inhibition uses lentiviral mediated expres-
sion of the light-activated halorhodopsin chloride pump from the 
microorganism Natronomonas pharaonis to hyperpolarize neurons 
in the CNS (Tonnesen et al., 2009). The most recent of these opti-
cal techniques are a collection of chimeras between rhodopsin 
and β2 and α1 adrenergic G-protein coupled receptors (GPCRs). 
Lentiviral mediated expression of these optoXR proteins in CNS 
tissues was found to modify firing rates of neurons in slice culture 
upon exposure to light consistent with the effects of neuronal Gαs 
or Gαq signal pathway activation to enhance or decrease firing 
respectively (Airan et al., 2009). Advantages of these optic tech-
niques include very rapid activation, however, limitations include 
poor penetration of light into whole organisms and the need of 
specialized equipment including light sources and fiber optics. 
Furthermore, lentiviral methods involve surgical procedures and 
the effects are usually transient.
Other studies have employed transgenic expression of certain 
wild type GPCRs to induce neuronal silencing. For example, selec-
tive targeted restoration of 5-HT1A serotonin receptor expression 
within a 5-HT1A receptor knockout background followed by con-
venient administration of receptor selective agonist has been found 
to be effective (Tsetsenis et al., 2007) in mice. Similarly, selective 
targeting of different Drosophila 5-HT receptors to defined tissues 
has also had some success to modulate tissue function (Kerr et al., 
2004). Whereas these methods utilizing native GPCRs are a promis-
ing and powerful avenue, care must be taken with respect to data 
interpretation due to potential confounding effects of endogenous 
neurotransmitters, and some of these models require specialized 
genetic backgrounds. Another approach involves heterologous tar-
geted expression of the Drosophila melanogaster allostatin peptide 
GPCR within the mouse CNS followed by application of allostatin, 
an insect peptide hormone not normally found in mammals, to 
induce neuronal silencing in the CNS (Tan et al., 2006; Wehr et al., 
2009). Peptides, however, have limited use because of their low solu-
bility and must therefore be directly applied to tissues of interest.
A new approach to study biological function and behaviors that 
circumvents many of the disadvantages of other technologies has 
been developed that combines the tissue specificity of transgenics 
with the rapid and reversible effects of pharmacological agents. 
The methodology involves targeted expression of GPCRs that have 
been modified to respond only to non-endogenous chemicals to 
rapidly and reversibly modulate effector pathway activity in defined 
tissues and neural circuits. Importantly, these receptors can be used 
to produce both short-term and long-term modulation of activity, 
and only require simple and convenient systemic administration 
of ligand by feeding or peripheral injection. Invasive procedures 
including stereotactic injection, and specialized equipment like fiber 
optics and light sources are not required. These modified G-protein 
receptors receptors have been termed: ‘Receptors Activated Solely 
by Synthetic Ligands (RASSLs)’ and ‘Designer Receptors Exclusively 
Activated by a Designer Drug (DREADDs)’ (Table 1).
GPcrs
G-protein coupled receptors are 7-α-helical transmembrane pro-
teins that transduce and amplify extracellular signals to multiple 
pathways inside the cell. GPCRs are the most widespread receptor 
class throughout the organism, and modulate not only cellular 
processes directly, but also the function of other receptor families, 
and are the primary mechanism of communication between cells 
(Kroeze et al., 2003; Armbruster and Roth, 2005). The physiological 
processes that GPCRs modulate are diverse and include neuro-
transmission, development, cardiovascular function, gut motility, 
and odor detection, among others. About 80% of hormones and 
Table  | The major RASSL and DREADD receptors grouped according to the primary G-protein activated. The	parent	receptor	of	each	is	listed.
Name  Parent receptor  Effector  Reference
α2A‑AR	 α2‑Adrenergic	 Gαi	 Pauwels	(2003)
Ro1,	Ro2	 κ‑Opioid	 Gαi	 Coward	et	al.	(1998)
Rog,	Rog‑μ,	Rog‑μA	 κ‑Opioid	 Gαi	 Scearce‑Levie	et	al.	(2005)
hM4D	 hM4	Muscarinic	 Gαi	 Armbruster	et	al.	(2007)
β2‑AR‑TREC	 β2‑Adrenergic	 Gαs	 Small	et	al.	(2001)
m	5‑HT4A	 m	5‑HT4A	 Gαs	 Claeysen	et	al.	(2003)
Rs1,	Rs1.1–3	 h	5‑HT4B	 Gαs	 Chang	et	al.	(2007)
Rm1,	Rm2	 MCR4	 Gαs	 Srinivasan	et	al.	(2007)
GsD	 rM3	 Gαs	 Geuttier	et	al.	(2009)
H1	 H1	 Gαq	 Bruysters	et	al.	(2005)
hM3D	 hM3	 Gαq	 Armbruster	et	al.	(2007)Frontiers in Molecular Neuroscience  www.frontiersin.org	 October	2009	 |	Volume	2	 |	Article	16	 |	 
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neurotransmitters involved in signal transduction are thought to 
act through GPCRs. Significantly, >50% of current drugs on the 
market target GPCR function as a major mechanism of therapeutics 
(Roth et al., 2004; Strachan et al., 2006). Thus, GPCRs remain the 
most popular family of targets used in drug discovery.
G-protein coupled receptors are functionally coupled to het-
erotrimeric G-proteins at the intracellular loops and C-terminus 
of the GPCR. Heterotrimeric G proteins are comprised of a Gα 
subunit and a dimeric Gβγ subunit, and are grouped into four 
classes: Gαs, Gαi/o, Gαq/11, and Gα12/13 (Gilman, 1987). Whereas 
Gαs stimulates the production of cAMP through activation of ade-
nylate cyclase, Gαi/o produces the opposite effect, and reduces lev-
els of intracellular cAMP through inhibition of adenylate cyclase. 
The Gαq subunit stimulates phospholipase-Cβ, which catalyzes 
the production of phosphoinositides and the release of intracel-
lular calcium, among other processes. Gα12/13 interacts with a 
number of effectors including RhoGEFs to modulate cell growth 
and cytoskeleton structure (Kelly et al., 2007).
Because of the widespread expression of GPCRs (Regard et al., 
2008), and the variety of effector pathways that they can couple 
to (Urban et al., 2007), targeted expression of modified GPCRs is 
an ideal tool to utilize to probe not only the role of how specific 
signal transduction pathways influence cellular function, but to 
also probe the role of specific tissues and neuronal circuits underly-
ing physiological and behavioral processes. The primary RASSL/
DREADD strategy is to engineer a collection of modified GPCRs, 
each coupling to different primary effector pathways, that respond 
to synthetic or non-endogenous compounds.
rASSLs
The first published report on the creation of a modified GPCR to 
respond to a non-endogenous ligand was by Strader et al. (1991). In 
the process of exploring the nature of ligand-receptor interactions 
for the β2-adrenergic receptor, a single point mutant (S113A) was 
found to eliminate binding of endogenous ligands while simul-
taneously conferring activity for a class of compounds with little 
affinity for the wild type receptor (Strader et al., 1991). Whereas the 
potencies of these synthetic compounds was relatively low at the 
modified β2AR, this work nevertheless demonstrated that GPCRs 
could be modified to lose native ligand recognition while maintain-
ing affinity for synthetic ligands. The Strader et al. (1991) study was 
thus an important proof-of-concept study for this approach.
The next major development was the creation of modified 
human kappa-opioid receptors with dramatically reduced affinity 
for the natural peptide ligands (1000-fold reduction), but retained 
affinity for small molecule drugs like bremazocine and spiradoline 
(Coward et al., 1998). Two receptor variants were created: Ro1 and 
Ro2. Ro1 is a chimeric receptor of the κ-opioid receptor contain-
ing the second extracellular loop of the delta opioid receptor, and 
Ro2 is essentially the Ro1 receptor with an additional mutation at 
the top of the sixth transmembrane helix. The overall design of 
the modified receptors arose from previous studies of chimeras 
between κ and δ receptors indicating that the second extracellu-
lar loop contains a major determinant for binding of a κ selec-
tive ligand, dynorphin. What was achieved by this manipulation 
was a Gαi-coupled κ-opioid receptor with significantly reduced 
binding to κ-specific peptides, but retained affinity for κ-selective 
small molecule synthetic ligands whose binding regions were not 
  determined by the second extracellular loop region (Coward et al., 
1998). These receptors were termed RASSLs, and when expressed 
in rat fibroblast cells found to be functional for inducing prolifera-
tion, a process known to be stimulated by Gαi signaling, with the 
synthetic ligand spiradoline (Coward et al., 1998).
Many studies using the Ro1 RASSLs were subsequently pub-
lished utilizing this receptor as a tool to explore the effects of 
activating the Gαi effector pathway in various tissues as defined 
by specific transgene targeting (Conklin et al., 2008; Pei et al., 
2008). The first transgenic mouse study detailed the conditional 
expression and activation of the Ro1 receptor in mouse heart, 
liver, and brain (Redfern et al., 1999). Activation of Gαi signal-
ing in the heart with the κ-opioid receptor agonist spiradoline 
produced significant and dose dependent bradycardia with a 
∼50% reduction in heart rate in less than a minute after drug 
administration (Redfern et al., 1999). In a subsequent study, it 
was found that the induction of expression of Ro1 in the heart 
induces cardiomyopathy in the absence of spiradoline (Redfern 
et al., 2000). Partially inhibiting expression of Ro1, treatment 
with the κOR antagonist nor-binaltomorphine, and treatment 
with pertussis toxin, restored normal function demonstrating 
that the heart defects were indeed due to excessive Gαi signal-
ing from the Ro1 receptor in the absence of ligand stimulation 
(Redfern et al., 2000). Significantly, these experiments indicate 
that there is a level of basal constitutive activity associated with 
the Ro1 receptor that is able to influence physiological processes 
in the absence of pharmacological activation. Nevertheless, this 
system has proven valuable as a new model for the study of dilated 
cardiomyopathy (Baker et al., 2001; McCloskey et al., 2008). The 
inducible doxycycline-responding Ro1 mouse strain was also uti-
lized by Sweger et al. (2007) to investigate the role of astrocytes 
in mouse brain. They created a transgenic κOR knockout mouse 
with conditional expression of Ro1 in astrocytes induced by dis-
continuation of feeding doxycycline and found that even in the 
absence of the κOR agonist spiradoline the mice developed severe 
hydrocephalus (Sweger et al., 2007) through mechanisms regulat-
ing CSF production, defining a new role for Gαi in astrocytes. 
Importantly, these results independently confirmed that the Ro1 
receptor is associated with a certain physiologically relevant level 
of constitutive activity.
This constitutive activity of Ro1 was exploited to investigate the 
role of Gαi signaling in bone development by Peng et al. (2008). 
It had been previously known that inactivation of Gαs signaling, 
the main effector pathway coupled to the PTH/PTHrP (PPR) 
receptors in osteoblasts, resulted in a reduction of bone forma-
tion and turnover (Sakamoto et al., 2005). Furthermore, that 
various means of indirectly inhibiting Gαi pathways, increased 
bone turnover (Peng et al., 2008). To directly test the role of Gαi 
signaling, the Ro1 receptor was conditionally expressed in mouse 
osteoblasts at various developmental time points from embryo-
genesis to weaning. At each time point, expression of the Ro1 
receptor resulted in decreased bone formation and turnover (Peng 
et al., 2008), mimicking the effects of Gαs inactivation. Together, 
these results indicate that proper bone formation results from a 
balance between Gαi and Gαs signaling activity in osteoblasts 
(Peng et al., 2008).Frontiers in Molecular Neuroscience  www.frontiersin.org	 October	2009	 |	Volume	2	 |	Article	16	 |	 
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An  interesting  study  using  the  doxycycline-responding  Ro1 
transgenic mice created by Redfen and colleagues was to examine 
the nature of the sweet and umami taste. Here, Ro1 was expressed 
in taste buds under the control of the T1R2 receptor promoter in 
T1R2 null mice. These mice responded to the κ-selective agonist 
spiradoline as control mice did to sweet taste, indicating that Gαi 
signaling through the T1R2 receptor is responsible for perception 
of sweet taste (Zhao et al., 2003).
Following the success of the initial Ro1 receptor, attempts were 
made to modify it. First, the Rog (RASSL opioid green) receptor 
was created by fusing GFP to the N-terminus of Ro1 to visualize 
receptor localization in the living cell (Scearce-Levie et al., 2005). 
After validating its ability to internalize upon agonist stimulation, 
signaling, and RASSL function, subsequent modifications included 
mutation of the four C-terminal phosphorylation sites to alanine 
(Rog-A), replacement of the entire C-terminus with the μ-opioid 
receptor (Rog-μ), and mutation of five C-terminal serine and 
glutamic acid residues of the Rog-μ receptor to alanine (Rog-μA) 
(Scearce-Levie et al., 2005). The loss of C-terminal phosphoryla-
tion sites in the Rog-A resulted in a significant reduction in ago-
nist induced internalization and a resistance to desensitization, 
however maximal cAMP inhibition was unaffected (Scearce-Levie 
et al., 2005). The Rog-μ receptor demonstrated increased agonist 
induced receptor internalization, as was predicted based upon the 
ability of the μ receptor to more readily internalize than the δ recep-
tor (Scearce-Levie et al., 2005). Whereas the Rog-μA receptor was 
predicted to be resistant to agonist induced internalization as the 
Rog-A receptor was, it surprisingly demonstrated constitutive inter-
nalization (Scearce-Levie et al., 2005). Addition of an antagonist, 
nor-BNI, was found to rescue cell surface expression (Scearce-Levie 
et al., 2005). Another physiological effect, adenylate cyclase superac-
tivation, was examined in these receptors. Long-term activation of 
Gαi signaling pathways can lead to an increase in adenylate cyclase 
activity and an enhanced response to forskolin stimulation over 
baseline conditions (Watts and Neve, 2005). Neither the Rog-μ nor-
Rog-μA receptors showed this effect after overnight treatment with 
spiradoline followed by forskolin stimulation (Scearce-Levie et al., 
2005). The authors speculated that it is not constitutive activity of 
Gαi from the Ro1 receptors that is responsible for cardiomyopathy 
observed in their previous studies, but rather an increase in Gαs 
signaling through adenylate cyclase superactivation that produces 
the phenotype (Scearce-Levie et al., 2005). It is possible that these 
newly modified Ro1-related RASSLs will address this issue as well 
as others.
Through a series of structure/function studies, another modified 
Gαi coupled receptor, the α2A-adrenergic receptor, was demon-
strated to have RASSL-like properties. Based upon previous work 
predicting the importance of two conserved serine residues within 
the putative transmembrane binding site the serine at position 200, 
and the serine at position 204 were each mutated to alanine and 
the resulting variants pharmacologically characterized. The result-
ing receptors had reduced (S200A), to negligent (S204A) affinity 
and activity for the native ligand, but high affinity and activity for 
certain classes of drug including synthetic imidazoline derivatives 
(Pauwels and Colpaert, 2000). Interestingly, several α2A-adrenergic 
receptor antagonists, including atipamezole and SKF86466, retained 
antagonist  properties  at  the  S200A  variant  but  demonstrated 
  significant partial agonist activity at the S204A receptor (Pauwels 
and Colpaert, 2000). Significantly, these studies demonstrated that 
aspects of functional selectivity can be potentially engineered in 
to a RASSL where the response of a receptor to a particular ligand 
is not only lost or retained in mutant RASSL variants, but can be 
fundamentally altered to a different response.
There have been three independent RASSL families developed 
to probe Gαs signaling. The first was an attempt to modify the 
β2-adrenergic receptor as a tool for use in gene therapies and create 
a ‘modified therapeutic receptor–effector complex’. In the human 
β2-adrenergic receptor, glutamine at position 27 was mutated to 
glutamate to reduce ligand-induced receptor internalization, aspar-
tate at position 113 was mutated to serine to alter ligand bind-
ing properties, 15 potential phosphorylation sites were changed 
to alanine, and the entire open reading frame of the rat Gαs was 
fused to the C-terminus coding region (Small et al., 2001). This 
modified receptor complex was found to be unresponsive to cata-
cholamines, but responsive to a single tested ligand L158870 at 
micromolar concentrations (Small et al., 2001). Due to the low 
potency of the modified receptor complex to the synthetic ligand 
its utility in vivo is likely limited.
The second approach at developing a Gαs RASSL involved 
modifying the serotonin 5-HT4A receptor. Key amino acids in the 
native ligand binding pocket were deduced based upon the pub-
lished crystal structure of the β-adrenergic receptor to identify 
Asp100 in TM3, which was predicted to interact with the amine in the 
indole ring of serotonin. Mutation of this Asp to Ala in the mouse 
5-HT4A receptor significantly reduced binding as well as activation 
of the receptor by serotonin and other tryptamines with respect to 
adenylate cyclase activation, while maintaining affinity and activity 
for other ligands without a protonated amine in the core structure 
(Claeysen et al., 2003). Interestingly, a number of antagonists at the 
native receptor were found to have agonist activity with respect to 
adenylate cyclase at the modified receptor (Rs1) (Claeysen et al., 
2003). This may allow for selective activation of the modified recep-
tor in animal models, while keeping native receptors inactive, some-
thing not possible with the Ro1 receptors. In a subsequent study, 
conditional expression of the Rs1 receptor in transgenic mouse 
osteoblasts resulted in increased bone mass in the absence of acti-
vating ligand, presumably by constitutive Gαs signaling from the 
Rs1 receptor (Hsiao et al., 2008). These bone-enhancing effects 
were observed to be different from a mouse expressing a constitu-
tively activated form of the Gαs-coupled PPR receptor, indicating 
that additional factors are differentially recruited to the receptors 
to mediate physiological effects.
To refine the RASSL characteristics of a receptor like Rs1, a series 
of modifications of the human 5-HT4B D100A receptor, which has 
high constitutive adenylate cyclase activity, were created (Chang 
et al., 2007). To reduce constitutive activity two separate muta-
tions were made, based upon previous reported studies examining 
structure and activity, changing Asp at position 66 to Asn (Rs1.2), 
and Trp at position 272 to Ala. Although each resulting RASSL had 
significantly reduced constitutive adenylate cyclase activity, there 
was also a large reduction in the levels of activation by the ligand 
zacopride, limiting their utility (Chang et al., 2007). Nevertheless, 
the RASSLs were significantly stimulated by agonist. An interesting 
feature of the Rs1 receptor includes functional selectivity where Frontiers in Molecular Neuroscience  www.frontiersin.org	 October	2009	 |	Volume	2	 |	Article	16	 |	 
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certain classes of ligand predominantly activate Gαs, while other 
classes, represented by zacopride, also induce coupling to Gαq. 
Surprisingly, the ability of zacopride to induce coupling to Gαq was 
lost in the two mutant 5-HT4B RASSLs (Chang et al., 2007).
In an attempt to create a predominantly Gαq-coupled RASSL, 
the  intracellular  loops  of  the  human  Rs1  were  replaced  with 
those from the Gαq-coupled human 5-HT2C receptor to create 
Rs1-5-HT2C (Rs1.1). In this process, 12 different chimeras were 
created and tested that each had different splicing junctions and 
combinations of intracellular loops. It was found that replacement 
of the second or third intracellular loops eliminated both Gαs and 
Gαq activity, and only replacement of the C-terminus was able to 
increase coupling to Gαq (Chang et al., 2007). This new recep-
tor, Rs1-C-5-HT2C, however, still had significant constitutive and 
  ligand-induced Gαs activity. Following similar techniques utilizing 
intracellular domains from the human 5-HT1A receptor, attempts 
were made to engineer a Gαi-couple RASSL from Rs1. Replacement 
of the third intracellular loop was found to abolish Gαs and Gαq 
activity and to confer Gαi activity to the Rs1-i3-5-HT1A (Rs1.3) 
receptor (Chang et al., 2007). The potency of this effect, however, 
was weak thus limiting the utility of this receptor. Importantly, 
these studies with the Rs1 series of receptors demonstrated that 
it was possible to continue to modify a RASSL to alter and refine 
physiological properties to something more desirable as a tool for 
in vivo use.
The third approach to develop a Gαs coupled RASSL involved 
modifying the melanocortin-4 receptor (MCR4). An extensive 
review of previous work examining the location and functional 
result of individual mutations in the MCR4 led to the identification 
of five candidate mutations for further study as potential RASSLs 
(Srinivasan et al., 2007). Of these, two were designated RASSLs: 
L106P-MCR4  (Rm1),  and  D122A-MCR4  (Rm2).  The  native 
RCM4 has significant constitutive basal activity associated with 
Gαs signaling, and although Rm1 has a 30% reduction in activity, 
Rm2 has a nearly twofold increase in basal activity over the native 
receptor (Srinivasan et al., 2007). Importantly, neither Rm1 nor-
Rm2 respond to native melanocortin peptides, but do respond to 
nanomolar concentrations of the synthetic MCR4 selective ligand 
THIQ with respect to measured cAMP release (Srinivasan et al., 
2007).
The third major class of G-protein effector is Gαq, and one 
attempt has been made to generate a RASSL coupled to this path-
way. Based upon previous structure function studies examining 
ligand binding properties, the phenylalanine at position 435 of the 
human H1 receptor was mutated to an alanine and the resulting 
receptor characterized (Bruysters et al., 2005). Rather than assess 
Gαq coupling by measuring PI turnover or calcium mobilization, 
a luciferase reporter assay for NFkB activity was used to measure 
activity. This was based upon previous work that demonstrated 
direct functional coupling of Gαq/11 to NFkB activation (Bakker 
et al., 2001). Therefore, RASSL activity from this receptor can only 
be reliably extended to activation of the NFkB signaling pathway. 
Interestingly, whereas the F453A H1 receptor variant maintained 
affinity for histamine, affinity and potency at NFkB activation 
increased up to 1000-fold for certain synthetic ligands (Bruysters 
et al., 2005). In the case of ClPheHA, potency was increased from 
an EC50 of ∼1 mM at the native receptor to ∼1 nM at the F453A 
variant. Rather than engineering loss of affinity and potency for 
native ligand while retaining those properties for a synthetic lig-
and, greatly enhancing affinity and potency for a synthetic ligand 
through receptor modification was demonstrated here to be a new 
strategy to develop a RASSL. The F453A H1 receptor has negligent 
basal constitutive activity with respect to NFkB signaling, however, 
additional pathways coupled to Gαq have yet to be investigated, as 
well as the utility of this receptor to study in vivo processes.
Of significant concern with nearly all RASSLs created thus far is 
the presence of physiologically relevant basal constitutive activity 
with the primary Gα effector protein. Whereas this may effectively 
allow functional analysis of an effector pathway under certain con-
ditions, constitutive activity present from embryogenesis has the 
potential to seriously confound results examining acute function. 
Another considerable shortcoming of the conventional RASSLs is 
that they by and large utilize synthetic ligands that have significant 
affinity and potency for the endogenous wild type receptor as well 
as potential off-target actions. Therefore, ligands used to stimulate 
RASSLs in vivo could induce behaviors and physiological processes 
from native receptors and confound results. Nonetheless, based 
on the large number of important papers, conventional RASSLs 
continue to be widely used with great success.
drEAdds
Ideally, a modified receptor would have no basal constitutive activ-
ity, and respond to a synthetic ligand that had no natural targets 
within the organism. To develop such a receptor system we followed 
a novel directed molecular evolution approach to generate a col-
lection of modified GPCRs termed DREADDs (Armbruster et al., 
2007). This strategy involved choosing a biologically inert metabo-
lite of clozapine, clozapine-N-oxide (CNO) as the synthetic ligand, 
and the human M3 receptor (M3R) for initial mutagenesis. Whereas 
the parent compound clozapine has affinity at multiple GPCRs, 
including high affinity and weak partial agonist activity for the 
M3R, the metabolite CNO was shown to lack appreciable affinity for 
any receptor by screening of nearly the entire relevant recepterome 
(Armbruster et al., 2007). A yeast model system where activation 
of the heterologously expressed modified rat M3R was required for 
cell growth (Erlenbach et al., 2001) was used as a screening platform 
for random mutagenesis to generate a set of mutants that were each 
activated by clozapine. A subset of these clones were selected for a 
second round of mutagenesis and selection for activation by 1 μM 
CNO, followed by a third round of mutagenesis and selection for 
growth on 5 nM CNO to generate a final collection of two modi-
fied M3 receptors with high affinity for CNO (Armbruster et al., 
2007) (Figure 1). Fortuitously, loss of affinity for the native ligand, 
acetylcholine, as well as carbachol was lost during this process. 
Whereas these modified rat M3 receptors demonstrated functional 
activation by CNO and insensitivity to acetylchole, they had high 
basal activity with respect to Gαq signaling and PI turnover in 
human HEK T cells. Based upon the results of the yeast screening 
experiments, a focused library of mutant full length human M3 
receptors was created and screened in HEK T cells to identify a 
receptor demonstrating high affinity for CNO, extremely low affin-
ity for acetylcholine, and minimal constitutive activity associated 
with Gαq signaling and PI turnover (Armbruster et al., 2007). The 
final receptor, hM3D, contained two point mutations with tyrosine Frontiers in Molecular Neuroscience  www.frontiersin.org	 October	2009	 |	Volume	2	 |	Article	16	 |	 
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FiGuRE  | Pharmacological profiles of an rM∆i receptor mutant selected 
during directed molecular evolution for CNO responsiveness. (A)	
Experimental	design	for	directed	evolution	of	mammalian	GPCRs	in	yeast	to	
create	DREADDs.	(1)	Libraries	of	randomly	mutated	rM3∆i3	receptors	were	
produced	by	mutagenic	PCR;	(2)	yeast‑expressing	mutant	receptors	activated	by	
synthetic	ligands	(e.g.,	CNO)	were	selected	for	by	growth	on	nutrient	deficient	
medium;	(3)	mutants	were	verified	by	secondary	liquid	growth	assays	in	96‑well	
plates;	(4)	plasmid	DNA	was	isolated	from	yeast;	(5)	clones	were	retransformed	
into	yeast	to	pharmacologically	profile	mutants	by	liquid	growth	assays,	and	those	
with	desirable	properties	were	sequenced	and	remutagenized	for	subsequent	
rounds	of	selection	to	yield	receptors	with	higher	potency.	(B)	Optical	density	at	
650	nm	of	liquid	cultures	of	yeast	transformed	with	either	wild	type,	clone	‘‘G2’’	
(first	library,	10	μM	clozapine	screen),	clone	‘‘9’’	(second	library,	1	μM	CNO	
screen),	or	clone	‘‘118’’	(third	library,	5‑nM	CNO	screen)	rM3∆i3	receptors	
incubated	with	ACh	(n),	clozapine	(¨),	or	CNO	(E).	Data	shown	are	mean	±	SEM	
values	of	a	representative	experiment	performed	with	two	independent	yeast	
transformants	grown	for	each	clone.	Figure	used	with	permission:	Copyright	
(2007)	National	Academy	of	Sciences,	USA	Armbruster	et	al.	(2007).Frontiers in Molecular Neuroscience  www.frontiersin.org	 October	2009	 |	Volume	2	 |	Article	16	 |	 
Nichols	and	Roth	 Engineered	GPCRs
at position 149 mutated to cystine, and alanine at position 239 
mutated to glycine (Armbruster et al., 2007). Importantly, not only 
was CNO able to activate Gαq signaling and PI turnover, but CNO 
was also shown to activate MAPK signaling through interactions 
with β-arrestin, indicating that coupling to multiple effector path-
ways was preserved in the DREADD receptor. Mutation of the con-
served tyrosine and glycine residues in the other human muscarinic 
receptors resulted in the creation of hM2D and hM4D DREADD 
receptors coupled to Gαi/o, and hM1D coupled to Gαq. Additional 
functionality of the hM4D was determined by demonstrating that 
stimulation of the receptor with CNO, but not with ACh, activated 
inwardly rectifying potassium channels (GIRKs) in both transfected 
HEK cells and transfected hippocampal neurons (Armbruster et al., 
2007). These results indicate that the hM4D receptor has potential 
as a tool for in vivo neuronal silencing.
To develop the final Gαs coupled DREADD (GsD), we modified 
the rat M3D receptor by replacing the second and third intracellular 
loops with the corresponding loops from the Gαs-coupled turkey 
β1-adrenergic receptor (Geuttier et al., 2009). Transgenic mouse 
lines expressing the hM3D and GsD receptors in pancreatic beta-
cells have been made that show stimulation of either receptor has 
significant effects on beta-cell function including aspects of glucose 
tolerance and insulin release (Geuttier et al., 2009). Additional 
transgenic mouse studies with all three DREADD receptors are 
currently being performed to analyze the role of G-protein sig-
naling in a variety of tissues (Figure 2). We have demonstrated 
remote control of neuronal activity in mice expressing the hM3D 
receptor in hippocampus (Alexander et al., 2009). Administration 
of CNO to these transgenic mice led to both increases in hippoc-
ampal neuronal activity as well as behavioral modifications includ-
ing increased locomotor activity and seizures in a dose dependent 
fashion (Alexander et al., 2009). In slice cultures, the increases in 
neuronal activity from a single pulse of CNO returned to baseline 
levels in about 60 min. The locomotor effects of systemic CNO, 
however, did not return to baseline levels for about 9 h (Alexander 
et al., 2009). Importantly, these data indicate that this system is 
reversible with in vitro cellular effects of CNO extinguishing more 
rapidly than the in vivo behavioral effects.
We have recently created transgenic Drosophila melanogaster 
expressing the Gαs-coupled hM4D, Gαi-coupled rM3D-βar, and 
Gαq-coupled hM1D receptors under the control of the bipartite 
GAL4/UAS system. The GAL4/UAS system is a genetic method to 
FiGuRE  | General strategy to achieve inducible, tissue-specific expression 
of DREADDs. The	upper	panel	shows	the	basic	strategy	to	generate	tissue	
specific	expression	of	DREADDs	in	mouse	brain.	Double	transgenic	animals	are	
made	where	one	element	contains	a	tissue	specific	promotor	(P‑TS)	driving	
expression	of	the	tetR‑VP16	fusion	protein,	and	the	other	contains	the	
tetracycline	response	element	(TetRE),	followed	by	a	minimal	CMV	promoter	
driving	expression	of	HA‑tagged	DREADDs.	Whereas	both	transgenic	elements	
are	present	in	every	cell	throughout	the	body,	expression	of	tetR‑VP19	is	only	in	
promoter	defined	areas	(e.g.	PET‑1	for	5‑HT	neurons,	GFAP	for	neuronal	
precursors	and	DARPP‑32	for	medium	spiny	neurons)	and	transgenic	receptor	
expression	is	limited	to	the	defined	tissue	(upper	center	and	right	panel).	When	
doxycycline	is	present	(DOX),	it	binds	to	the	tetR	factor	and	blocks	it	from	
interacting	with	the	TetRE,	preventing	transcription	of	DREADDs	(upper	left	
panel).	The	lower	panels	show	preliminary	success	with	CAMKII‑tet,	which	
achieves	forebrain‑specific	expression;	in	this	set	of	founders,	high	levels	of	
expression	were	achieved	in	hippocampus.Frontiers in Molecular Neuroscience  www.frontiersin.org	 October	2009	 |	Volume	2	 |	Article	16	 |	 
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express transgenes selectively in defined tissues (Brand and Perrimon, 
1993). In preliminary studies we have targeted DREADD expression 
to distinct neural circuits and have found that behaviors are dramati-
cally altered when adult flies expressing DREADDS are fed CNO 
(unpublished results). Importantly, wild type and parental strains 
maintained on food containing CNO (at least to 10 mM) exhibit 
no overt abnormal developmental or behavioral effects, indicating 
that the effects of CNO on the transgenic flies expressing DREADDs 
are indeed due to DREADD activation. Given the conservation of 
biological processes between mammalian systems and the power 
of the fly as a genetic model (Nichols, 2006), studies performed in 
the fly are likely to be informative to both insect and mammalian 
models with respect to elucidation of signal transduction pathways 
and molecular processes underlying neuronal function as they relate 
to behaviors. Furthermore, this system is anticipated to be useful in 
the fly to probe the role of signal transduction pathways and discreet 
tissues in developmental processes.
Aside from using DREADDs to directly probe the role of individual 
signal transduction pathways in physiological processes and the role 
of specific tissues and circuits in behaviors, the hM4D receptor has 
recently proven to be a valuable tool in understanding mechanisms 
of allosteric modulation in GPCRs. A known allosteric modulator of 
the M4 receptor, LY2033298, was shown to act cooperativity with the 
orthosteric binding site to restore affinity and functionality of acetyl-
choline to the orthosteric site of the hM4D receptor (Nawaratne et al., 
2008). These muscarinic DREADD receptors, and potentially other 
similarly modified receptors, may represent novel tools to screen 
for allosteric modulators that act solely through interactions at dis-
tinct allosteric sites and have cooperativity with the orthosteric site. 
Compounds that would be able to restore affinity and activity to the 
native ligand would therefore potentially represent novel therapeutics 
that enhance the ability of native ligand to activate its receptor.
SummAry
An exciting and powerful method of probing the role of G-protein 
effector signaling, as well as the function of discreet tissues and 
neural circuits in mediating physiological processes and behaviors 
has recently been developed and refined. The first generation of engi-
neered GPCRs, RASSLs, were primarily rationally designed based 
upon structure/function studies to eliminate native ligand binding, 
while maintaining affinity for synthetic ligands. These receptors 
have been used to generate conditionally expressing transgenic mice, 
where they have been used to study how G-protein effector pathways 
affect various processes including heart function, bone growth, and 
brain development. They have also been used to define the function 
of other GPCRs as well as particular tissues, as they were used to elu-
cidate the receptor and effector pathway underlying the perception 
of sweet taste. Advantages that this system offers are the ability to very 
rapidly turn on and off signaling pathways by simply administering 
a synthetic ligand. Importantly, because GPCRs and their associated 
effector pathways are ubiquitous throughout an organism, studies 
are not limited to examining the native role of the particular receptor 
a RASSL is derived from, but can be used to define the function of 
entire tissues and neural circuits in a more systems-based approach. 
These first generation RASSLs, unfortunately, are frequently associ-
ated with physiologically relevant basal constitutive activity, as well 
as response to synthetic ligands that also target the endogenous wild 
type receptors. Whereas these properties may be advantageous for 
some studies, they likely present certain limitations and challenges 
for widespread use.
The next generation of engineered GPCRs, DREADDs, created 
through a process of directed molecular evolution overcome many 
of the limitations present in the first generation RASSLs. DREADDS 
have negligent basal constitutive activity associated with them, and 
are activated by synthetic ligands with no appreciable affinity for any 
of the known receptorome. Additionally, CNO has minimal activity 
at a variety of relevant kinases (Figure 3). Transgenic expression 
models in both mouse and fly have validated their functionality to 
probe both physiological processes and complex behaviors. Given 
the advantages of the DREADD receptors over the RASSLs, there 
are certain caveats that must be considered for them, as well as for 
the RASSLs, involving expression levels.
Under most normal transgenic conditions, expression levels 
are likely high, such that even under non-activated conditions the 
stoichiometric balance between receptor and precoupled effector 
may be perturbed such that the normal function of the tissue and 
circuit may be affected. Furthermore, the presence of high levels 
of activated receptor may induce activation of effector pathways 
not normally functionally coupled to the particular GPCR, con-
founding results. To achieve the most relevant data for a particular 
system, expression levels should be determined, and manipulated if 
possible, with those having expression closest to naturally occurring 
GPCRs used for experimentation. Nevertheless, both RASSLs and 
DREADDs present a very effective tool to elucidate biological func-
tion and behaviors. Advantages over other current systems include 
the specificity of transgenic targeting, the convenience of systemic 
administration of small molecule drugs with no other appreciable 
biological targets within the organism, rapidity and reversibility of 
effect, and no need for specialized equipment.
FiGuRE  | Clozapine-N-oxide is devoid of activity at essential neuronal 
protein kinases. As	is	shown,	CNO	at	a	screening	concentration	of	10	μM	is	
devoid	of	appreciable	agonist	or	antagonist	activity	at	a	large	number	of	the	
neuronal	kinases	implicated	in	signaling	(V.	Setola	and	B.	L.	Roth,	unpublished	
observations).Frontiers in Molecular Neuroscience  www.frontiersin.org	 October	2009	 |	Volume	2	 |	Article	16	 |	 
Nichols	and	Roth	 Engineered	GPCRs
Lin, J. Y., Lin, M. Z., Steinbach, P., and 
Tsien, R. Y. (2009). Characterization of 
engineered channelrhodopsin variants 
with improved properties and kinetics. 
Biophys. J. 96, 1803–1814.
Martin, J. R., Keller, A., and Sweeney, S. T. 
(2002). Targeted expression of tetanus 
toxin: a new tool to study the neuro-
biology of behavior. Adv. Genet. 47, 
1–47.
McCloskey, D. T., Turcato, S., Wang, G. Y., 
Turnbull, L., Zhu, B. Q., Bambino, T., 
Nguyen,  A.  P.,  Lovett,  D.  H., 
Nissenson, R. A., Karliner, J. S., and 
Baker, A. J. (2008). Expression of a Gi-
coupled receptor in the heart causes 
impaired Ca2+ handling, myofilament 
injury, and dilated cardiomyopathy. 
Am. J. Physiol. Heart Circ. Physiol. 294, 
H205–H212.
McGuire, S. E., Roman, G., and Davis, R. L. 
(2004). Gene expression systems in 
Drosophila: a synthesis of time and 
space. Trends Genet. 20, 384–391.
Nagel, G., Szellas, T., Huhn, W., Kateriya, S., 
Adeishvili, N., Berthold, P., Ollig, D., 
Hegemann,  P.,  and  Bamberg, E. 
(2003).  Channelrhodopsin-2,  a 
directly light-gated cation-selective 
membrane channel. Proc. Natl. Acad. 
Sci. U.S.A. 100, 13940–13945.
Nagel,  G.,  Szellas,  T.,  Kateriya,  S., 
Adeishvili, N.,  Hegemann, P., 
and  Bamberg,  E.  (2005). 
Channelrhodopsins: directly light-
gated cation channels. Biochem. Soc. 
Trans. 33, 863–866.
Nakashiba, T., Young, J. Z., McHugh, T. J., 
Buhl, D. L., and Tonegawa, S. (2008). 
Transgenic inhibition of synaptic 
transmission reveals role of CA3 out-
put in hippocampal learning. Science 
319, 1260–1264.
Nawaratne, V., Leach, K., Suratman, N., 
Loiacono,  R.  E.,  Felder,  C.  C., 
Armbruster, B.  N.,  Roth,  B.  L., 
Sexton, P. M., and Christopoulos, A. 
(2008). New insights into the function of 
M4 muscarinic acetylcholine receptors 
gained using a novel allosteric modula-
tor and a DREADD (designer receptor 
exclusively activated by a designer drug). 
Mol. Pharmacol. 74, 1119–1131.
Nichols, C. D. (2006). Drosophila mela-
nogaster neurobiology, neurophar-
macology, and how the fly can inform 
central nervous system drug discovery. 
Pharmacol. Ther. 112, 677–700.
Nitabach, M. N., Blau, J., and Holmes, T. C. 
(2002).  Electrical  silencing  of 
Drosophila pacemaker neurons stops 
the free-running circadian clock. Cell 
109, 485–495.
Pauwels, P. J., and Colpaert, F. C. (2000). 
Disparate ligand-mediated Ca(2) 
responses  by  wild-type,  mutant 
Ser(200)Ala  and  Ser(204)Ala 
alpha(2A)-adrenoceptor: G(alpha15) 
fusion proteins: evidence for multiple 
rEfErEncES
Aiba,  A.,  and  Nakao,  H.  (2007). 
Conditional  mutant  mice  using 
  tetracycline-controlled gene expres-
sion system in the brain. Neurosci. 
Res. 58, 113–117.
Airan, R. D., Thompson, K. R., Fenno, L. E., 
Bernstein, H., and Deisseroth, K. 
(2009). Temporally precise in vivo 
control of intracellular signalling. 
Nature 458, 1025–1029.
Alexander, G. M., Rogan, S. C., Abbas, A. I., 
Armbruster, B. N., Pei, Y., Allen, J. A., 
Nonneman,  R.  J.,  Hartmann, J., 
Moy, S. S.,  Nicolelis, M. A., 
McNamara, J. O., and Roth, B. L. 
(2009). Remote control of neuronal 
activity in transgenic mice expressing 
evolved G protein-coupled receptors. 
Neuron 63, 27–39.
Armbruster, B. N., Li, X., Pausch, M. H., 
Herlitze, S., and Roth, B. L. (2007). 
Evolving the lock to fit the key to 
create a family of G protein-coupled 
receptors potently activated by an inert 
ligand. Proc. Natl. Acad. Sci. U.S.A. 104, 
5163–5168.
Armbruster, B. N., and Roth, B. L. (2005). 
Mining the receptorome. J. Biol. Chem. 
280, 5129–5132.
Baker, A. J., Redfern, C. H., Harwood, M. D., 
Simpson, P. C., and Conklin, B. R. 
(2001). Abnormal contraction caused 
by expression of G(i)-coupled receptor 
in transgenic model of dilated cardio-
myopathy. Am. J. Physiol. Heart Circ. 
Physiol. 280, H1653–H1659.
Bakker, R. A., Schoonus, S. B., Smit, M. J., 
Timmerman, H., and Leurs, R. (2001). 
Histamine H(1)-receptor activation 
of nuclear factor-kappa B: roles for 
G beta gamma- and G alpha(q/11)-
subunits in constitutive and agonist-
mediated signaling. Mol. Pharmacol. 
60, 1133–1142.
Brand, A. H., and Perrimon, N. (1993). 
Targeted gene expression as a means 
of altering cell fates and generating 
dominant phenotypes. Development 
118, 401–415.
Bruysters, M., Jongejan, A., Akdemir, A., 
Bakker, R. A., and Leurs, R. (2005). 
A G(q/11)-coupled mutant histamine 
H(1) receptor F435A activated solely 
by synthetic ligands (RASSL). J. Biol. 
Chem. 280, 34741–34746.
Chang, W. C., Ng, J. K., Nguyen, T., 
Pellissier, L., Claeysen, S., Hsiao, E. C., 
and Conklin, B. R. (2007). Modifying 
ligand-induced and constitutive sig-
naling of the human 5-HT4 receptor. 
PLoS ONE 2, e1317. doi: 10.1371/jour-
nal.pone.0001317.
Claeysen, S., Joubert, L., Sebben, M., 
Bockaert, J., and Dumuis, A. (2003). 
A  single  mutation  in  the  5-HT4 
receptor (5-HT4-R D100(3.32)A) 
generates  a  Gs-coupled  receptor 
activated exclusively by synthetic 
ligands (RASSL). J. Biol. Chem. 278, 
699–702.
Conklin, B. R., Hsiao, E. C., Claeysen, S., 
Dumuis,  A.,  Srinivasan,  S., 
Forsayeth, J. R.,  Guettier,  J.  M., 
Chang, W. C., Pei, Y., McCarthy, K. D., 
Nissenson, R. A., Wess, J., Bockaert, J., 
and Roth, B. L. (2008). Engineering 
GPCR  signaling  pathways  with 
RASSLs. Nat. Methods 5, 673–678.
Coward, P., Wada, H. G., Falk, M. S., 
Chan, S. D., Meng, F., Akil, H., and 
Conklin, B. R. (1998). Controlling 
signaling with a specifically designed 
Gi-coupled receptor. Proc. Natl. Acad. 
Sci. U.S.A. 95, 352–357.
Drago, J., Padungchaichot, P., Wong, J. Y., 
Lawrence,  A.  J.,  McManus,  J.  F., 
Sumarsono,  S.  H.,  Natoli,  A.  L., 
Lakso, M., Wreford, N., Westphal, H., 
Kola, I., and Finkelstein, D. I. (1998). 
Targeted expression of a toxin gene to 
D1 dopamine receptor neurons by cre-
mediated site-specific recombination. 
J. Neurosci. 18, 9845–9857.
Erlenbach, I., Kostenis, E., Schmidt, C., 
Hamdan, F. F., Pausch, M. H., and 
Wess, J. (2001). Functional expres-
sion of M(1), M(3) and M(5) mus-
carinic acetylcholine receptors in yeast. 
J. Neurochem. 77, 1327–1337.
Gaveriaux-Ruff, C., and Kieffer, B. L. 
(2007). Conditional gene targeting in 
the mouse nervous system: insights 
into brain function and diseases. 
Pharmacol. Ther. 113, 619–634.
Geuttier, J. M., Gautam, D., Scarselli, M., 
Ruiz de Azula, I., Li, J. H., Rosemond, E., 
Ma, X., Gonzales, F., Armbruster, B., 
Lu, H., Roth, B. L., and Wess, J. (2009). 
A chemical-genetic approach to study 
G protein regulation of β cell function 
in vivo. Proc. Natl. Acad. Sci. U.S.A. (in 
press).
Gilman, A. G. (1987). G proteins: trans-
ducers of receptor-generated signals. 
Annu. Rev. Biochem. 56, 615–649.
Hsiao,  E.  C.,  Boudignon,  B.  M., 
Chang, W. C., Bencsik, M., Peng, J., 
Nguyen, T. D.,  Manalac,  C., 
Halloran, B. P., Conklin, B. R., and 
Nissenson, R. A. (2008). Osteoblast 
expression of an engineered Gs-
  coupled  receptor  dramatically 
increases bone mass. Proc. Natl. Acad. 
Sci. U.S.A. 105, 1209–1214.
Kelly, P., Casey, P. J., and Meigs, T. E. 
(2007). Biologic functions of the G12 
subfamily of heterotrimeric g proteins: 
growth, migration, and metastasis. 
Biochemistry 46, 6677–6687.
Kerr, M., Davies, S. A., and Dow, J. A. 
(2004). Cell-specific manipulation 
of second messengers; a toolbox for 
integrative physiology in Drosophila. 
Curr. Biol. 14, 1468–1474.
Kroeze, W. K., Sheffler, D. J., and Roth, B. L. 
(2003). G-protein-coupled receptors at 
a glance. J. Cell. Sci. 116, 4867–4869.
ligand-activation  binding  sites. 
Br. J. Pharmacol. 130, 1505–1512.
Pauwels, P. J. (2003). Unravelling multiple 
ligand-activation binding sites using 
RASSL receptors. Trends Pharmacol. 
Sci. 24, 504–507.
Pei, Y., Rogan, S. C., Yan, F., and Roth, B. L. 
(2008). Engineered GPCRs as tools 
to modulate signal transduction. 
Physiology (Bethesda) 23, 313–321.
Peng, J., Bencsik, M., Louie, A., Lu, W., 
Millard, S., Nguyen, P., Burghardt, A., 
Majumdar,  S.,  Wronski,  T.  J., 
Halloran, B.,  Conklin,  B.  R.,  and 
Nissenson, R. A. (2008). Conditional 
expression of a Gi-coupled receptor in 
osteoblasts results in trabecular osteo-
penia. Endocrinology 149, 1329–1337.
Redfern, C. H., Coward, P., Degtyarev, M. Y., 
Lee, E. K., Kwa, A. T., Hennighausen, L., 
Bujard, H., Fishman, G. I., and Conklin, 
B. R. (1999). Conditional expression 
and signaling of a specifically designed 
Gi-coupled receptor in transgenic 
mice. Nat. Biotechnol. 17, 165–169.
Redfern, C. H., Degtyarev, M. Y., Kwa, A. T., 
Salomonis, N., Cotte, N., Nanevicz, T., 
Fidelman, N., Desai, K., Vranizan, K., 
Lee, E. K., Coward, P., Shah, N., 
Warrington, J. A., Fishman, G. I., 
Bernstein,  D.,  Baker,  A.  J.,  and 
Conklin, B. R. (2000). Conditional 
expression of a Gi-coupled receptor 
causes ventricular conduction delay 
and a lethal cardiomyopathy. Proc. 
Natl. Acad. Sci. U.S.A. 97, 4826–4831.
Regard, J. B., Sato, I. T., and Coughlin, S. R. 
(2008).  Anatomical  profiling  of 
G protein-coupled receptor expres-
sion. Cell 135, 561–571.
Roth, B. L., Sheffler, D. J., and Kroeze, W. K. 
(2004). Magic shotguns versus magic 
bullets: selectively non-selective drugs 
for mood disorders and schizophrenia. 
Nat. Rev. Drug Discov. 3, 353–359.
Sakamoto, A., Chen, M., Nakamura, T., 
Xie, T., Karsenty, G., and Weinstein, L. S. 
(2005). Deficiency of the G-protein 
alpha-subunit G(s)alpha in osteob-
lasts leads to differential effects on 
trabecular and cortical bone. J. Biol. 
Chem. 280, 21369–21375.
Scearce-Levie, K., Lieberman, M. D., 
Elliott, H. H., and Conklin, B. R. 
(2005). Engineered G protein coupled 
receptors reveal independent regula-
tion of internalization, desensitization 
and acute signaling. BMC Biol. 3, 3.
Schroll, C., Riemensperger, T., Bucher, D., 
Ehmer, J., Voller, T., Erbguth, K., 
Gerber, B., Hendel, T., Nagel, G., 
Buchner, E., and Fiala, A. (2006). 
Light-induced activation of distinct 
modulatory neurons triggers appeti-
tive or aversive learning in Drosophila 
larvae. Curr. Biol. 16, 1741–1747.
Small, K. M., Brown, K. M., Forbes, S. L., 
and Liggett, S. B. (2001). Modification 
of the beta 2-adrenergic receptor to Frontiers in Molecular Neuroscience  www.frontiersin.org	 October	2009	 |	Volume	2	 |	Article	16	 |	 0
Nichols	and	Roth	 Engineered	GPCRs
Ryba, N. J., and Zuker, C. S. (2003). 
The receptors for mammalian sweet 
and umami taste. Cell 115, 255–266.
Conflict of Interest Statement: The 
authors declare that the research was 
conducted in the absence of any com-
mercial or financial relationships that 
could be construed as a potential conflict 
of interest.
Received: 29 May 2009; paper pend-
ing published: 08 July 2009; accepted: 12 
September 2009; published online: 23 
October 2009.
Citation:  Nichols  CD  and  Roth  BL 
(2009) Engineered G-protein coupled 
receptors are powerful tools to inves-
tigate biological processes and behav-
iors. Front. Mol. Neurosci. 2:16. doi: 
10.3389/neuro.02.016.2009
Copyright © 2009 Nichols and Roth. This 
is an open-access article subject to an exclu-
sive license agreement between the authors 
and the Frontiers Research Foundation, 
which permits unrestricted use, distribu-
tion, and reproduction in any medium, 
provided the original authors and source 
are credited.
engineer a receptor–effector complex 
for gene therapy. J. Biol. Chem. 276, 
31596–31601.
Srinivasan, S., Santiago, P., Lubrano, C., 
Vaisse, C., and Conklin, B. R. (2007). 
Engineering  the  melanocortin-4 
  receptor to control constitutive and 
ligand-mediated GS signaling in vivo. 
PLoS ONE 2, e668. doi: 10.1371/journal.
pone.0000668.
Strachan, R. T., Ferrara, G., and Roth, B. L. 
(2006). Screening the receptorome: an 
efficient approach for drug discovery 
and target validation. Drug Discov. 
Today 11, 708–716.
Strader, C. D., Gaffney, T., Sugg, E. E., 
Candelore, M. R., Keys, R., Patchett, A. A., 
and Dixon, R. A. (1991). Allele-specific 
activation of genetically engineered 
receptors. J. Biol. Chem. 266, 5–8.
Sweger, E. J., Casper, K. B., Scearce-Levie, K., 
Conklin, B. R., and McCarthy, K. D. 
(2007). Development of hydrocepha-
lus in mice expressing the G(i)-coupled 
GPCR Ro1 RASSL receptor in astro-
cytes. J. Neurosci. 27, 2309–2317.
Tan, E. M., Yamaguchi, Y., Horwitz, G D., 
Gosgnach, S., Lein, E. S., Goulding, M., 
Albright, T. D., and Callaway, E. M. 
(2006). Selective and quickly reversible 
inactivation of mammalian neurons in 
vivo using the Drosophila allatostatin 
receptor. Neuron 51, 157–170.
Tonnesen, J., Sorensen, A. T., Deisseroth, K., 
Lundberg, C., and Kokaia, M. (2009). 
Optogenetic control of epileptiform 
activity. Proc. Natl. Acad. Sci. U.S.A. 
106, 12162–12167.
Tsetsenis, T., Ma, X. H., Lo Iacono, L., Beck, 
S. G., and Gross, C. (2007). Suppression 
of conditioning to ambiguous cues by 
pharmacogenetic inhibition of the den-
tate gyrus. Nat. Neurosci. 10, 896–902.
Urban,  J.  D.,  Clarke,  W.  P.,  von 
Zastrow, M., Nichols, D. E., Kobilka, B., 
Weinstein, H., Javitch, J. A., Roth, B. L., 
Christopoulos, A., Sexton, P. M., 
Miller, K.  J.,  Spedding,  M.,  and 
Mailman, R. B. (2007). Functional 
selectivity  and  classical  concepts 
of  quantitative  pharmacology. 
J. Pharmacol. Exp. Ther. 320, 1.
Watts, V. J., and Neve, K. A. (2005). 
Sensitization of adenylate cyclase 
by Galpha i/o-coupled receptors. 
Pharmacol. Ther. 106, 405–421.
Wehr, M., Hostick, U., Kyweriga, M., 
Tan, A., Weible, A. P., Wu, H., Wu, W., 
Callaway, E. M., and Kentros, C. (2009). 
Transgenic silencing of neurons in 
the mammalian brain by expression 
of the allatostatin receptor (AlstR). 
J. Neurophysiol. 2009; 0: 00480.2009v1 
[Epub ahead of print].
Wells, T., and Carter, D. A. (2001). Genetic 
engineering of neural function in 
transgenic rodents: towards a compre-
hensive strategy? J. Neurosci. Methods 
108, 111–130.
Wulff,  P.,  Goetz,  T.,  Leppa,  E., 
Linden, A. M., Renzi, M., Swinny, J. D., 
Vekovischeva, O. Y.,  Sieghart, W., 
Somogyi, P., Korpi, E. R., Farrant, M., 
and Wisden, W. (2007). From syn-
apse to behavior: rapid modula-
tion of defined neuronal types with 
engineered GABAA receptors. Nat. 
Neurosci. 10, 923–929.
Yu,  C.  R.,  Power,  J.,  Barnea,  G., 
O’Donnell, S.,  Brown,  H.  E., 
Osborne, J., Axel, R., and Gogos, J. A. 
(2004). Spontaneous neural activity 
is required for the establishment and 
maintenance of the olfactory sensory 
map. Neuron 42, 553–566.
Zhao, G. Q., Zhang, Y., Hoon, M. A., 
Chandrashekar,  J.,  Erlenbach,  I., 